Athenex, Inc. (ATNX): Price and Financial Metrics


Athenex, Inc. (ATNX): $0.43

0.02 (+5.76%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ATNX POWR Grades


  • ATNX scores best on the Growth dimension, with a Growth rank ahead of 87.28% of US stocks.
  • The strongest trend for ATNX is in Value, which has been heading up over the past 179 days.
  • ATNX's current lowest rank is in the Quality metric (where it is better than 2.44% of US stocks).

ATNX Stock Summary

  • ATNX has a market capitalization of $98,474,854 -- more than approximately only 14.76% of US stocks.
  • As for revenue growth, note that ATNX's revenue has grown -16.77% over the past 12 months; that beats the revenue growth of only 8.03% of US companies in our set.
  • In terms of volatility of its share price, ATNX is more volatile than 97.45% of stocks we're observing.
  • Stocks that are quantitatively similar to ATNX, based on their financial statements, market capitalization, and price volatility, are SNCR, ITRI, SPOK, TELL, and THTX.
  • Visit ATNX's SEC page to see the company's official filings. To visit the company's web site, go to www.athenex.com.

ATNX Valuation Summary

  • In comparison to the median Healthcare stock, ATNX's price/sales ratio is 13.16% lower, now standing at 3.3.
  • ATNX's price/earnings ratio has moved up 5.2 over the prior 51 months.
  • Over the past 51 months, ATNX's price/earnings ratio has gone up 5.2.

Below are key valuation metrics over time for ATNX.

Stock Date P/S P/B P/E EV/EBIT
ATNX 2021-08-31 3.3 2.2 -2.7 -3.4
ATNX 2021-08-30 3.3 2.1 -2.7 -3.4
ATNX 2021-08-27 3.3 2.1 -2.7 -3.4
ATNX 2021-08-26 3.2 2.1 -2.6 -3.3
ATNX 2021-08-25 3.2 2.1 -2.6 -3.3
ATNX 2021-08-24 3.1 2.0 -2.6 -3.2

ATNX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ATNX has a Quality Grade of F, ranking ahead of 2.45% of graded US stocks.
  • ATNX's asset turnover comes in at 0.31 -- ranking 148th of 681 Pharmaceutical Products stocks.
  • XNCR, DRRX, and VRTX are the stocks whose asset turnover ratios are most correlated with ATNX.

The table below shows ATNX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.310 0.344 -0.445
2021-03-31 0.384 0.334 -0.479
2020-12-31 0.416 0.340 -0.548
2020-09-30 0.477 0.409 -0.574
2020-06-30 0.472 0.394 -0.716
2020-03-31 0.404 0.436 -0.726

ATNX Price Target

For more insight on analysts targets of ATNX, see our ATNX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $9.17 Average Broker Recommendation 1.71 (Moderate Buy)

ATNX Stock Price Chart Interactive Chart >

Price chart for ATNX

ATNX Price/Volume Stats

Current price $0.43 52-week high $4.82
Prev. close $0.41 52-week low $0.41
Day low $0.41 Volume 494,900
Day high $0.44 Avg. volume 1,006,649
50-day MA $0.50 Dividend yield N/A
200-day MA $1.33 Market Cap 48.42M

Athenex, Inc. (ATNX) Company Bio


Athenex Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. The company was founded in 2003 and is based in Buffalo, New York.


ATNX Latest News Stream


Event/Time News Detail
Loading, please wait...

ATNX Latest Social Stream


Loading social stream, please wait...

View Full ATNX Social Stream

Latest ATNX News From Around the Web

Below are the latest news stories about Athenex Inc that investors may wish to consider to help them evaluate ATNX as an investment opportunity.

Athenex names new CFO

Athenex (NASDAQ:ATNX) has appointed Joe Annoni as its new chief financial officer and officer of the company, effective immediately. Prior to joining Athenex, Annoni served as Managing Director with GFW Partners, a boutique advisory firm. Prior to GFW, Joe was a founding member of NHA Capital where he led private equity and...

Seeking Alpha | February 22, 2022

Athenex Announces Appointment of Chief Financial Officer

BUFFALO, N.Y., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that Mr. Joe Annoni will join Athenex as its new Chief Financial Officer and Officer of the Company, effective immediately. Mr. Annoni is an accomplished financial professional and has enjoyed a multi-faceted career in private equity,

Yahoo | February 22, 2022

Athenex Announces Completion of Sale of Dunkirk Manufacturing Facility

BUFFALO, N.Y., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today the close of the sale of its leasehold interest in a manufacturing facility in Dunkirk, New York, to ImmunityBio, Inc. (NASDAQ: IBRX), for approximately $40 million. “We are pleased with the opportunity to partner with ImmunityBio on t

Yahoo | February 15, 2022

Athenex to Present at the 11th Annual SVB Leerink Global Healthcare Conference

BUFFALO, N.Y., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that Johnson Lau, CEO and Board Chairman, and Daniel Lang, President, Athenex Cell Therapy, will present at the 11 th Annual SVB Leerink Global healthcare Conference on Thursday, February 17, 2022, at 3:00 P.M. ET.

GlobeNewswire | February 9, 2022

Inside the Athenex-ImmunityBio deal — and the California company's employment plans

A relationship that began at American Pharmaceutical Partners, which had a longtime plant on Grand Island, led the immunotherapy and cell therapy company to Dunkirk.

Yahoo | January 13, 2022

Read More 'ATNX' Stories Here

ATNX Price Returns

1-mo -12.88%
3-mo -50.31%
6-mo -68.38%
1-year -90.57%
3-year -97.81%
5-year -97.48%
YTD -68.38%
2021 -87.70%
2020 -27.57%
2019 20.33%
2018 -20.19%
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.541 seconds.